I believe the CEO is pursuing sale of the DEP cancer drug platform the sale will include all current in house drugs along with a large patent portfolio and listed applications. The sale will create a large cash chest for Starpharma to pursue their existing products and applications, the CEO hinted at this possibility in a recent interview. As far as potential value of moneyterizing the platform I am not sure something approaching $400m I would guess. This is just my opinion and not financial advice.
Sale of DEP platform?
Add SPL (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
9.9¢ |
Change
0.001(1.02%) |
Mkt cap ! $41.39M | |||
| Open | High | Low | Value | Volume |
| 9.8¢ | 10.0¢ | 9.8¢ | $21.81K | 220.4K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 15344 | 9.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 10.0¢ | 246867 | 12 |
View Market Depth
| Last trade - 13.24pm 07/11/2024 (20 minute delay) ? |
| SPL (ASX) Chart |